Background Combining anti-angiogenesis agents with cytotoxic agents for the treatment of malignant gliomas may affect the cytotoxic drug distribution by normalizing the blood-brain barrier (BBB). This study examines the intratumoral concentration of temozolomide (TMZ) in the presence and absence of the pan-VEGF receptor tyrosine kinase inhibitor, cediranib. Methods Seven nude rats bearing U87 intracerebral gliomas had a microdialysis probe centered within the tumor. Ten-days after tumor implantation, TMZ (50 mg/kg) was given orally. The extracellular fluid (ECF) concentrations of TMZ within the tumor were assessed via microdialysis for 6 h following TMZ administration. Cediranib (6 mg/ kg) was then given orally, and 12 h later, TMZ was readministered with subsequent microdialysis collection. A subset of animals also underwent functional MRI to assess angiogenesis in vivo at post-inoculation days 12 and 21, before and after the cediranib treatment. Results After dosing of oral TMZ only, ECF-TMZ mean-C max and area under the concentration curve(AUC 0-? ) within the tumor were 0.59 lg/mL and 1.82 lg h/mL, respectively. Post-cediranib, ECF-TMZ mean-C max and AUC 0-? were 0.83 lg/mL and 3.72 ± 0.61 lg h/mL within the tumor, respectively. This represented a 1.4-fold (p = 0.3) and 2.0-fold (p = 0.06) increase in the ECF-TMZ C max and AUC 0-? , respectively, after cediranib administration. In vivo MRI measurements of the various vascular parameters were consistent with a BBB ''normalization'' profile following cediranib treatment. Conclusions In the U87 intracerebral glioma model, within the first day of administration of cediranib, the intratumoral concentrations of TMZ in tumor ECF were slightly, but not statistically significantly, increased when compared to the treatment of TMZ alone with radiographic evidence of a normalized BBB.
Introduction
Advances in glioma therapy have resulted in improved median survival among patients with glioblastoma multiforme (GBM) from 9 to 20 months [2, 17, 22] . However, after four decades of research, only three agents have been approved for treatment of GBM; orally delivered temozolomide (TMZ), locally delivered polifeprosan 20 with carmustine implanted and most recently, bevacizumab (Avastin Ò ). Bevacizumab was the first anti-angiogenic drug approved by the FDA for the treatment of recurrent GBM [7, 13] . Bevacizumab is an intravenous monocloncal antibody against vascular endothelial growth factor (VEGF)-A. Cediranib, (AZD2171, AstraZeneca), in contrast, is an oral tyrosine kinase inhibitor that simultaneously targets the intracellular domain of all three VEGF receptor tyrosine kinases, c-Kit and platelet-derived growth factor receptor alpha and beta (PDGFR-a and PDGFR-b). It is an indoleether quinazoline with a molecular weight of 450.5 that has demonstrated potent ATP-competitive inhibition of VEGF signaling predominantly through inhibition of the tyrosine kinase of VEGFR-2/Flk-1/KDR [23] . When administered once daily, cediranib has been shown to normalize tumor vessels in patients with recurrent GBM starting as early as 1 day after the treatment and lasting at least 28 days [3] .
Recent phase II clinical studies tested cediranib monotherapy for recurrent GBM patients and demonstrated increased progression-free survival (PFS) with steroidsparing effects and reduction in tumor-associated vasogenic edema [3] . Advanced MRI revealed that in the setting of cediranib, there was decreased contrast enhancement, reduction in average blood vessel size, vascular permeability and decrease in blood flow and volume collectively suggesting a vascular normalizing effect [3, 9] .
Combining angiogenesis inhibitors with chemotherapy in GBMs may allow improved delivery of drug to tumor due to the decreased interstitial fluid pressure and improved perfusion secondary to the phenomenon of vascular ''normalization [3, 21] .'' A competing hypothesis is that anti-angiogenic therapies may impair delivery of cytotoxic drugs to brain tumors by reducing the BBB permeability often associated with gliomas. It is difficult to empirically predict how anti-angiogenesis drugs will affect the brain concentration of concomitantly administered chemotherapeutic agents. Prior pre-clinical studies with TMZ and anti-angiogenic therapy suggest that intratumoral concentrations of the chemotherapeutic agent can be affected either positively or negatively [9, 15, 16] . Thus, it is crucial to investigate the pharmacokinetic (PK) relationship between anti-angiogenic agents and TMZ to determine how such combinations can be used most effectively in patients [9] .
In this study, we determined the brain extracellular fluid (ECF) concentration of TMZ when TMZ is administered with and without cediranib. We employed microdialysis techniques to assess intratumoral PK using the intracranial U87 human glioma model in athymic rats. We also utilized functional MRI to assess in vivo changes in the tumor vasculature following cediranib administration.
Materials and methods

Materials
Temodar (Schering Corporation, a subsidiary of Merck & Co., Inc. NJ, USA) was commercially purchased from the Johns Hopkins Hospital pharmacy. Cediranib (Selleck Chemicals, Houston, TX, USA) was purchased from Selleck Chemicals. CMA12 microdialysis brain probes [membrane length 2 mm, shaft diameter 0.6 mm, shaft length 14 mm, membrane diameter 0.5 mm, polyarylethersulfone (PAES) membrane], CMA 120 bowl system for freely moving animals, CMA 402 syringe pump, microsyringes 10 mL glass with piston stroke 60 mm were commercially purchased from CMA (CMA Microdialysis Inc. MA, USA). The study was approved by the Johns Hopkins Animal Care and Use Committee (ACUC), and all procedures were conducted in compliance with their regulations.
Cell culture
The U87 human glioma cell line (from Dr. Laterra, Johns Hopkins University, Baltimore, MD, USA [12] ) was grown in MEM with Earle salts and L-glutamine (MEM 1*Mediatech, Inc.) supplemented with 10 % fetal bovine serum (Gemini Bioproducts, Inc.), 2mMol/L sodium pyruvate (Mediatech, Inc.), 0.1 mmol/L MEM-nonessential amino acids (Mediatech, Inc.) and penicillin-streptomycin (Mediatech, Inc.). The cells were grown at 37°C in a humidified incubator with 5 % CO 2 .
Implantation of tumor cells and microdialysis probes
Seven male athymic rats, 200-300 g each, were anesthetized by intraperitoneally administering 0.6-0.8 ml of a ketamine (15 mg) and xylazine (1.5 mg) cocktail. Animals were secured in a stereotactic apparatus, and their scalp was shaved and cleaned. A midline incision was made, the skull was exposed and 2 mm hole was drilled 2 mm left and 2 mm posterior to the bregma. After placing the guide cannula with the dummy catheter and securing by using dental cement (Geristore Syringeable value kit A2, Denmat, Santa-Maria, CA, USA) in a depth of 4 mm from the skull, 2 9 10 6 U87 cells were inoculated with a 26-gauge needle attached to the stereotactic frame, at a depth of 5 mm into the left striatum as described previously [9] . At the end of the inoculation process, the needle was slowly removed from the brain, and the skin was clipped with staples. The rats then were returned to cages and received standard rat diet and water ad libitum. Animals were monitored daily for new neurological symptoms and body weight.
Microdialysis methodology and ECF sample collection Eleven days after intracranial tumor inoculation, the 2 mm CMA12 microdialysis catheter was inserted in the place of the dummy catheter. The intracerebral microdialysis catheter was perfused in a rate of 1 lL/min with lactated Ringer's using a CMA microsyringe pump for 1 h before the administration of TMZ. TMZ (50 mg/kg, dissolved in water) was given orally, and for the next 6 h, brain ECF dialysate was collected every hour. After 6 h of dialysate collection, in vivo dialysate recovery was performed. At the end of the first collection day, the microdialysis catheter was stored in lactated Ringer's, and the dummy catheter was re-inserted into the cannula instead.
A single dose of 6 mg/kg cediranib dissolved in 1 % Tween was administered by oral gavage [11] . The rats were returned to their cages with ad libitum diet, water and activity. Twelve hours after the cediranib dosing, rats were anesthetized again with ketamine and xylazine. After replacing the dummy catheter with intracerebral microdialysis catheters, the system was perfused in a rate of 1 lL/ min with lactated Ringer's for 1 h before the administration of TMZ. TMZ (50 mg/kg, dissolved in water) was again given by oral gavage, and brain ECF dialysate was collected every hour for the next 6 h. In vivo dialysate recovery experiments were done again at the conclusion of collection. All ECF dialysate samples were stored in -80°C until analyzed for drug concentrations using liquid chromatography-tandem mass spectrometry (LC/MS/MS) as described previously [9] .
In vivo assessment of probe recovery Estimation of in vivo recovery was done at the end of each collection period (pre-and post-cediranib). Using the retrodialysis method, the probes were perfused with lactated Ringer's solution containing TMZ at a rate of 1 lL/min to determine the in vivo probe recovery [24] . The percentage relative recovery calculated as follows [5, 14] .
where C perfusate is the drug concentration (2 lg/mL) in the perfusate, and C dialysate is the drug concentration in the microdialysate. For one animal (animal 6) where samples were not obtained, the average in vivo recovery for the other animals was used for further calculations. The recovery was utilized to estimate the ECF concentration of TMZ [5, 14] .
Pharmacokinetic analysis
Pharmacokinetic parameters were calculated for raw and estimated ECF values by standard non-compartmental analysis using WinNonlin version 5.3 (Pharsight Corporation, Mountain View, CA, USA) [8] . The observed maximum plasma concentration (C max ) of TMZ and the time of C max after oral administration (T max ) were recorded. The area under the plasma concentration-time curve (AUC) was calculated using the log-linear trapezoidal rule and extrapolated to infinity (AUC 0-? ) by dividing the last quantifiable concentration by the terminal disposition rate constant (k z ). The k z was determined from the slope of the terminal phase of the concentration-time profile and utilized to calculate the half-life (T 1/2 ) by dividing 0.693 by k z .
In vivo MRI
Tumor-bearing mice brains were imaged in vivo on a 9.4T vertical bore MRI scanner. Four mice were scanned at 12-day post-inoculation (i.e. D12) of the U87 glioma cell line (two controls and two treated with cediranib once daily till the animals were euthanized) and another four at 3-week post-inoculation (i.e. D21) (three controls and one treated with cediranib). All mice were scanned using the following sequences and parameters: (i) T Á 3=2 is proportional to average blood vessel size [18] . Using the Analysis of Functional NeuroImages (AFNI) software package, voxelwise pre-and post-contrast R Ã 2 and R 2 maps were calculated by fitting the GE and SE signal intensity versus TE curves to the following mono-exponential plus constant noise model:
Maps were then calculated by subtracting pre-contrast
Tumor regions of interest (ROI) were manually drawn, and contralateral ROIs were determined by reflecting the tumor ROIs across the brain midlines. The histogram distributions of the total/ microvascular blood volume and vessel size parameters in the tumor and contralateral ROIs were compared.
Statistical analysis
Wilcoxon matched-pairs signed-rank test was used to determine the difference between the PK parameters before and after cediranib dosing by using JMP Statistical Discovery Software version 7.0.1 (SAS Institute, Cary, NC, USA). A p \ 0.05 was considered significant.
Results
Pharmacokinetic Measurements of TMZ in brain ECF
The mean corrected TMZ ECF C max on the tumor side, following the first dose of TMZ but before cediranib was administered was 0.59 ± 0.22 lg/mL (mean ± SD) which occurred at a median time of 1.50 h, and area under the concentration curve (AUC 0-? ) was 1.82 ± 0.64 lg h/mL. After the administration of cediranib, there was a 1.4-fold and 2.0-fold increase in the C max and AUC 0-? , respectively. Specifically, the mean corrected TMZ ECF C max on the tumor side after cediranib was dosed was 0.83 ± 0.45 lg/mL (p value = 0.22 for raw data, and p value = 0.30 for corrected data), which occurred at a median time of 1.50 h, and AUC 0-? was 3.72 ± 0.61 lg h/mL (p value = 0.06 for raw and for corrected data). The half-life was slightly prolonged after cediranib administration (1.7 ± 0.3 h pre-cediranib vs. 2.0 ± 0.9 h post-cediranib, p [ 0.05). Although there was a suggestion of higher concentrations of TMZ in tumor after cediranib, none of the measures reached statistical significance (Table 1 ; Fig. 1 ).
In vivo MRI changes in the tumor vasculature after treatment with cediranib Representative in vivo MRI maps of DR ) and microvascular and (DR 2 ) blood volume of the control tumor were comparable to that of the contralateral ROI at D12, but were markedly elevated at D21. In contrast, treated tumors exhibited lower blood volumes at both time points. The average vessel size for both tumor and contralateral ROIs was similar in the D12 control, but the vessel size in the treated D12 tumor was lower compared to the contralateral ROI. A similar effect on vessel size was not apparent at the later time point. Additionally, pooled histograms of DR contralateral ROIs (Fig. 3) show that for the D12 control group, the tumor and contralateral distributions were similar for all three in vivo MRI vascular parameters (Fig. 3a-c) , while for the D12 treated group, the distributions for all three parameters were shifted toward lower values (Fig. 3d-f ). In contrast, DR Ã 2 and DR 2 were elevated in the control D21 tumors compared to the contralateral ROIs (Fig. 3g-h ). The treated D21 tumor exhibited DR Ã 2 and DR 2 distributions that were shifted toward the lower contralateral values (Fig. 3j-k) . Both control and treated D21 tumors exhibited DR 
Discussion
This study assessed whether concurrent therapy of an oral anti-angiogenesis tyrosine kinase inhibitor given with a cytotoxic drug has a synergistic or opposing effect by investigating the intratumoral concentration of TMZ via microdialysis catheters before and after cediranib treatment in a U87 xenograft intracranial glioma model. Previously, microdialysis studies suggest variable effects when combining anti-angiogenesis agents with cytotoxic drugs. A multi-targeted receptor tyrosine kinase inhibitor, sunitinib, showed a synergistic effect when combined with TMZ in an intracerebral glioma model in the mouse [15] . However, a 50 % reduction in TMZ was reported in tumor concentrations when administered with the angiogenesis inhibitor TNP-470 in a similar murine model [16] . Utilizing intratumoral microdialysis in the U87 intracerebral glioma model, no significant change in ECF concentration of TMZ was observed before or 36 h after bevacizumab dosing [9] . Several pre-clinical and clinical studies have suggested that normalization of tumor vessels induced by cediranib may provide a time-limited window of normalization that may be optimal for combination therapy with cytotoxic drugs [3, 11, 21] . Cediranib in combination with lomustine was tested in 325 patients with recurrent GBM in a randomized, multicenter Phase III study. There was no significant difference in progression PFS between cediranib monotherapy versus cediranib and lomustine [1] . In the current study, the intratumoral concentrations of TMZ in tumor ECF showed a trend toward being elevated 1 day after cediranib was administered, with PK results showing 2-and 1.4-folds increase in the intratumoral AUC 0-? and C max of TMZ in U87 xenograft tissue. However, this increase was not statistically significant, most likely due to the limited sample size of the current study and the variability of PK parameters inter-animal. Another possible explanation may be the timing of the microdialysis measurement related to the cediranib dosing. It has been suggested that the tumor vessel normalization phenomena may start a day after cediranib administration and continue for 28 days [3, 9] . Therefore, it may be possible that the microdialysis measurements in this study were started too early to capture the maximal effect.
Microdialysis has potential advantages for PK studies since it allows for estimation of drug exposure at the site of action over a given period of time [4, 20, 24] . However, this technique has several limitations as discussed previously [9] .While microdialysis probe insertion in rodent models increases BBB permeability after 3-4 days [23] , this effect normalizes over time. Therefore, in order to minimize the effect of possible BBB disruption, we started drug collection from the ECF 11 days after catheter placement. In order to measure the relative loss of the analyte diffusing from the perfusate into the ECF and make a valid comparison between the data obtained from microdialysis at different time points, the relative recovery was determined. There are several methods to assess relative recovery [24] . Since in vitro recovery tends to overestimate the in vivo recovery values [10] , in vivo recovery was assessed at the end of each microdialysis day. Our in vivo recovery values ranged between 69.4 ± 13.9 and 70.1 ± 10.8 %, which were relatively high compared to previously published microdialysis studies, suggesting the catheters were patent for the duration of the study [9, 10] .
Due to its sensitivity to the underlying vasculature, susceptibility contrast-based MRI is increasingly used to characterize the efficacy of various anti-angiogenic agents [19] . Evaluation of tumor imaging parameters one day after cediranib dosing was predictive of survival in patients with recurrent GBM [21] . In the current study, histogram analyses of the in vivo functional MRI data indicate that for the D12 control group, the tumor and contralateral distributions were similar for all three in vivo angiogenic parameters (i.e. total blood volume, microvascular blood volume and vessel size) while for the D12 treated group, the distributions for all three parameters were shifted toward lower values. The treated D21 tumor also exhibited DR Ã 2 and DR 2 distributions that were shifted toward the lower contralateral values. Collectively, these in vivo MRIderived total and microvascular blood volume data are consistent with our understanding of vascular normalization immediately following treatment with cediranib. Namely, following cediranib treatment the blood volume of the tumor vessels approaches that of the contralateral brain. In contrast, both control and treated D21 tumors exhibited vessel size distributions similar to the contralateral brain, indicating that different vessel populations may have been influenced by cediranib. Recently, Farrar et al. [6] . assessed the response of a mouse intracranial glioma model to cediranib treatment using analogous in vivo MRI biomarkers and made a similar observation showing decreased cerebral blood volume and microvascular blood volume post-treatment.
This study has several limitations. The study is based on relatively small number of animals. This is almost universally inherent to all microdialysis studies that are considered ''animal sparing'' technique. Moreover, we investigated the effect of a single dose of cediranib on intratumoral temozolomide concentration only within one day after cediranib was administered. We do not know how long the time frame of the ''normalization window'' lasts. We based the cediranib dose and timing of our measurement on previous work describing that the window of normalization following cediranib administration is started within one day after single dosing of cediranib [21] . The animal model used in this study also has limitations. The animal model used was the intracranial U87 xenograft that does not exhibit the necrotic core characteristic of the human GBM, and its invasion pattern is not prominent compare to other human glioma cell lines. Still this model is predictable, has reproducible growth patterns and has high expression of VEGF and exhibits profound angiogenesis, it allowed us to investigate the effect of anti-angiogenesis agent, cediranib, on the intratumoral concentration of TMZ. In order to assess the exact location of the microdialysis probe in the tumor, we performed H&E staining for all the rat brains and made sure that in all the animals, the probes were located in the center of the tumor. Our study provides PK data that shows that TMZ intratumoral concentrations do not decline in the setting of the oral tyrosine kinase inhibitor cediranib, despite its panantiangiogenesis effects and visualized normalization of the BBB. In fact, there is a suggestion that TMZ concentrations increased slightly after cediranib dosing in a U87 glioma xenograft model. However, this increase was not signficant due to the variability between animals. Overall, these findings suggest that with an agent such as TMZ that is known to cross the BBB relatively well, cediranib does not limit intratumoral concentration of TMZ when they are given concurrently. ) from tumor (red) and contralateral (blue) ROIs for the D12 (a-f) and D21 (g-l) groups, respectively. For the D12 control (D12 CTRL) group, the tumor and contralateral distributions were similar to all three in vivo MRI vascular parameters. However, for the D12-treated (D12 Tx) group, the distributions for all three in vivo MRI vascular parameters exhibited a shift toward lower values. In contrast, DR 
